OneSource Specialty Pharma Limited enters into strategic licensing agreement with Bhami’s Research Laboratory

Bangalore: OneSource Specialty Pharma Limited has entered into a strategic licensing agreement with Bhami’s Research Laboratory (BRL). This partnership will provide OneSource with access to BRL’s HILOPROÒ formulation technology, enabling the subcutaneous delivery of high-concentration biologic therapies.

The technology aims to reduce viscosity and facilitate the delivery of high-concentration biologic products, applicable across a broad spectrum of monoclonal antibodies and fusion proteins. Under the agreement, OneSource will offer BRL’s innovative formulation technology, enhancing its development and manufacturing services for both drug products and substances.

OneSource offers world-class capabilities across biologics, complex injectables and drug-device combination products, soft gelatin capsules and has demonstrated experience on different therapeutic modalities and technology platforms.

Commenting on the development Neeraj Sharma, Managing Director, OneSource said, "We are excited to partner with Bhami’s Research Laboratory, marking a significant step forward for OneSource in enhancing the subcutaneous delivery of high-concentration biologic therapies. BRL’s formulation technology offers promising capabilities to reduce viscosity and enable effective delivery of a wide spectrum of biologic products. The adoption of subcutaneous delivery for small-volume, low-viscosity biotherapeutics offers substantial benefits to patients compared to traditional intravenous injections, including improved healthcare accessibility, reduced hospitalisation requirements, lower overall treatment costs. This technology platform also complements our strong and demonstrated experience in biologics drug substance and drug delivery devices (such as auto-injectors and pens). We are looking forward to offering this technology to our existing and prospective customers, across innovative biologic and biosimilar products."

Commenting on the partnership Dr Surya Pai, Co-founder and Chief Executive Officer, BRL said, "Our globally patented high-concentration, low-viscosity protein drug delivery platform aims to optimise patient care by offering convenient, affordable, and safe treatment options. Together with OneSource, we look forward to setting new benchmarks in biopharmaceutical innovation and improving healthcare outcomes worldwide."